Joaquin Mateo

List of Publications by Year
in descending order

95 papers	14,673 citations	61857 43 h-index	42291 92 g-index
96 all docs	96 docs citations	96 times ranked	15522 citing authors

#	Article	IF	Citations
1	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
2	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	13.9	1,796
3	Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 382, 2091-2102.	13.9	1,327
4	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
5	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	3.3	839
6	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 162-174.	5.1	450
7	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 383, 2345-2357.	13.9	440
8	A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology, 2019, 30, 1437-1447.	0.6	437
9	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2018, 29, 1895-1902.	0.6	424
10	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 2017, 7, 1006-1017.	7.7	341
11	Secondary mutations in <scp>BRCA2</scp> associated with clinical resistance to a <scp>PARP</scp> inhibitor. Journal of Pathology, 2013, 229, 422-429.	2.1	287
12	PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology, 2015, 67, 795-802.	0.9	195
13	Genomics of lethal prostate cancer at diagnosis and castration resistance. Journal of Clinical Investigation, 2020, 130, 1743-1751.	3.9	180
14	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clinical Cancer Research, 2015, 21, 4586-4596.	3.2	171
15	Baseline neutrophilâ€“lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Annals of Oncology, 2015, 26, 750-755.	0.6	170
16	DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology, 2017, 71, 417-425.	0.9	169
17	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 4441-4453.	3.9	155
18	Sequencing of agents in castration-resistant prostate cancer. Lancet Oncology, The, 2015, 16, e279-e292.	5.1	141

#	Article	IF	Citations
19	Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 285-293.	0.9	125
20	Delivering precision oncology to patients with cancer. Nature Medicine, 2022, 28, 658-665.	15.2	125
21	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European Urology, 2016, 70, 985-992.	0.9	119
22	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical Cancer Research, 2018, 24, 5585-5593.	3.2	113
23	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 5981-5992.	3.2	107
24	An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. Targeted Oncology, 2016, 11, 401-415.	1.7	103
25	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European Urology, 2018, 73, 687-693.	0.9	99
26	Appraising iniparib, the PARP inhibitor that never wasâ€"what must we learn?. Nature Reviews Clinical Oncology, 2013, 10, 688-696.	12.5	81
27	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283, 168-177.	3.6	81
28	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discovery, 2021, 11, 2812-2827.	7.7	78
29	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. European Urology, 2021, 79, 200-211.	0.9	76
30	BRCA2 and Other DDR Genes in Prostate Cancer. Cancers, 2019, 11, 352.	1.7	72
31	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European Urology, 2019, 75, 184-192.	0.9	69
32	Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of Oncology, 2018, 29, 1554-1560.	0.6	65
33	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 676-685.	0.9	62
34	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nature Reviews Urology, 2015, 12, 37-47.	1.9	60
35	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 724-731.	0.9	59
36	Phenotypic diversity of circulating tumour cells in patients with metastatic castrationâ€resistant prostate cancer. BJU International, 2017, 120, E30-E44.	1.3	54

#	Article	IF	Citations
37	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology, 2021, 299, 109-119.	3.6	54
38	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. British Journal of Cancer, 2014, 111, 2248-2253.	2.9	52
39	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology, 2016, 280, 151-160.	3.6	51
40	Characterizing CDK12-Mutated Prostate Cancers. Clinical Cancer Research, 2021, 27, 566-574.	3.2	50
41	The promise of circulating tumor cell analysis in cancer management. Genome Biology, 2014, 15, 448.	3.8	47
42	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. ESMO Open, 2019, 4, e000480.	2.0	47
43	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. European Urology, 2021, 79, 762-771.	0.9	47
44	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. British Journal of Cancer, 2016, 114, 889-896.	2.9	46
45	Pan-cancer Analysis of Homologous Recombination Repairâ€“associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. Clinical Cancer Research, 2022, 28, 1412-1421.	3.2	46
46	Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 2020, 1, 1041-1053.	5.7	45
47	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 687-697.	3.2	43
48	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. European Journal of Cancer, 2021, 147, 74-83.	1.3	42
49	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clinical Cancer Research, 2022, 28, 1518-1530.	3.2	41
50	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.4	40
51	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease. Investigative Radiology, 2018, 53, 96-102.	3.5	36
52	Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. British Journal of Cancer, 2014, 111, 828-836.	2.9	34
53	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 280-284.	1.0	33
54	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, 2020, 26, 4777-4784.	3.2	31

#	Article	IF	Citations
55	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clinical Genitourinary Cancer, 2016, 14, 485-493.	0.9	30
56	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clinical Cancer Research, 2017, 23, 6070-6077.	3.2	30
57	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. European Urology, 2021, 79, 519-529.	0.9	30
58	A first-in-human study of the anti-Î±5Î²1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 1039-1046.	1.1	29
59	Novel drugs targeting the androgen receptor pathway in prostate cancer. Cancer and Metastasis Reviews, 2014, 33, 567-579.	2.7	29
60	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. European Urology, 2021, 80, 243-253.	0.9	28
61	Targeting DNA Repair. Cancer Journal (Sudbury, Mass), 2016, 22, 353-356.	1.0	27
62	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology, 2017, 28, 90-95.	0.6	24
63	Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. European Urology Oncology, 2018, 1, 71-77.	2.6	24
64	A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castrationâ€Resistant Prostate Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 277-285.	1.3	23
65	External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone. European Urology, 2014, 66, 8-11.	0.9	21
66	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	0.9	21
67	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. Cancer Treatment Reviews, 2020, 86, 102000.	3.4	19
68	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	1.3	19
69	Molecular Characterization and Clinical Utility of Circulating Tumor Cells in the Treatment of Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e197-e203.	1.8	16
70	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. Clinical Genitourinary Cancer, 2017, 15, e801-e807.	0.9	16
71	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. European Urology, 2022, 81, 37-47.	0.9	16
72	Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Current Oncology Reports, 2019, 21, 42.	1.8	15

#	Article	IF	Citations
73	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus, 2018, 4, 235-244.	1.6	14
74	Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.. Journal of Clinical Oncology, 2020, 38, 195-195.	0.8	11
75	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. Journal of Clinical Oncology, 2017, 35, TPS5091-TPS5091.	0.8	10
76	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precision Oncology, 2022, , .	1.5	10
77	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers, 2021, 13, 2334.	1.7	9
78	Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Molecular Diagnosis and Therapy, 2012, 16, 151-61.	1.6	8
79	Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer. Advances in Experimental Medicine and Biology, 2019, 1210, 279-300.	0.8	7
80	PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. European Urology, 2019, 76, 459-460.	0.9	5
81	Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.. Journal of Clinical Oncology, 2015, 33, 5014-5014.	0.8	5
82	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget, 2017, 8, 104430-104443.	0.8	5
83	Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion time: Insights from simulations, 9.4T imaging, and histology. Magnetic Resonance in Medicine, 2022, 88, 365-379.	1.9	5
84	Clinical implications of homologous recombination repair mutations in prostate cancer. Prostate, 2022, 82, .	1.2	4
85	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. Journal of Clinical Oncology, 2017, 35, 135-135.	0.8	3
86	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e577-e583.	1.8	2
87	Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?. European Urology, 2017, 72, 201-204.	0.9	2
88	Targeting DNA damage response systems to impact cancer care. Current Problems in Cancer, 2017, 41, 247-250.	1.0	2
89	Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC. European Urology Focus, 2016, 2, 465-466.	1.6	1
90	Acquiring evidence for precision prostate cancer care. Annals of Oncology, 2017, 28, 916-917.	0.6	1

#	Article	IF	Citations
91	Nanoparticles as theranostic vehicles in prostate cancer. Annals of Translational Medicine, 2019, 7, S29-S29.	0.7	1
92	Towards a New Classification for Metastatic Prostate Cancer. European Urology, 2019, 75, 383-384.	0.9	0
93	PARP Inhibitors. Current Clinical Urology, 2014, , 253-264.	0.0	0
94	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. Journal of Clinical Oncology, 2017, 35, 5071-5071.	0.8	0
95	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e577-e583.	1.8	0